ZURICH, March 21 (Reuters) - Lonza Group (LONN.S) said on Monday it signed a manufacturing agreement with Sweden's Oasmia Pharmaceutical (OASM.ST) for ovarian cancer drug candidate Cantrixil that was licensed by Oasmia from the Australian pharmaceutical company Kazia last year.
The European Union’s human medicines committee approved a ramp-up in manufacturing capacity for Moderna and Pfizer/BioNTech’s mRNA vaccines
Lonza invests in new production line in China
Sheba Medical Center, the largest hospital in the Middle East region, and Lonza, a global cell and gene therapy manufacturer, have treated multiple patients with CD19 CAR-T cell immunotherapy targeting B-cell malignancies, with three patients showing complete responses, and another patient is still being evaluated.
Lonza Extends Large-Scale MAb Commercial Supply Pact
Lonza, CN Bio Partner on Prevalidated Hepatocytes for Organ-on-a-chip Range
Lonza made new investments in GMP laboratories and mid-scale manufacturing assets at its API manufacturing center in Nansha, China. The investments, totaling over CHF 20 million ($21,789,934), will allow Lonza to provide a smoother transition from small-scale to large-scale manufacturing for customers while maintaining Lonza’s global quality and regulatory standards, according to Jan Vertommen, senior director, commercial development, Lonza.
20M CHF investment will include three 1,000L GMP trains and new development and GMP labs with HPAPI capabilities.
CellPoint, a cell therapy company developing CAR-T therapeutics for use at the point-of-care, announces an agreement with Lonza's Personalized Medicine Business Unit to employ Lonza's Cocoon® Platform for clinical manufacturing of CellPoint's CAR-T cell therapies at the point-of-care, more rapidly and at lower cost.